Affected by the epidemic, the development of the biological drug manufacturing (biopharmaceutical) industry is facing a good situation. Its revenue growth rate is higher than that of the entire pharmaceutical industry and most of the pharmaceutical detailed industries, and the profit margin is the first. 2020, the main business income of the biopharmaceutical industry reached 119.26 billion yuan, an increase of 7.6%year -on -year, accounting for 9.63%of the proportion of the pharmaceutical industry; the total profit was 24.96 billion yuan, accounting for 13.49%of the pharmaceutical industry. The status in the pharmaceutical industry is becoming more and more important. The fluctuations in the industry scale, the growth rate is higher than the overall overall pharmaceutical industry Driven and promoted the national policy, after 2013, my country's biopharmaceutical manufacturing industry has entered a stage of rapid development. In recent years, the growth rate has slowed down. The industry has entered a stable stage of development. From the perspective of the industry's main business income trend, the main business income of the biopharmaceutical industry in my country from 2013-2016 increased year by year, and the overall fluctuations after 2017 were fluctuating. 2019 that the country's category was revenue of the main business revenue of 247.92 billion yuan in the main business industry. In the first half of 2020, the main business income of the biopharmaceutical industry reached 119.26 billion yuan.
relative to the entire pharmaceutical industry and other mainstream sub -industries Biopharmaceutical is a small industry with a low market share, but its development potential is very huge, and the industry is developing faster. In 2019, the revenue growth rate of my country's biopharmaceutical industry reached 10.3%, and 7.6%in the first half of 2020, all higher than the overall growth rate of the pharmaceutical industry during the same period and the growth rate of pharmaceutical sub -industries such as the manufacturing and Chinese medicines.
The profit margin is rising, and the profit margin is higher than that of various pharmaceutical segments. In 2019, my country's biopharmaceutical industry has achieved a total profit of 48.54 billion yuan, an increase of 14%year -on -year, accounting for 14.04%of the proportion of the pharmaceutical industry; the total profit of the biopharmaceutical industry in the first half of 2020 was 24.96 billion yuan. In profit margins, the overall sales profit margin of the pharmaceutical industry in the first half of 2020 was 14.9%, an increase of 1.2 percentage points from the same period of the previous year (13.7%). In 2019, the profit margin of the biopharmaceutical industry reached 19.6%, and 20.9%in the first half of 2020, all of which were higher than the overall pharmaceutical industry and the profit margins of various sub -industries during the same period. Generally speaking, the industry's profit was better. The biopharmaceutical status is more important, and revenue and profit account for relatively high . From the above analysis, it can be seen that the status of the biopharmaceutical industry in the pharmaceutical industry is more important. More than 12%, the main business income accounts for more than 9%. In 2019, the proportion of income and profit of the main business of the biopharmaceutical industry reached 9.48%and 14.04%, respectively; in the first half of 2020, 9.63%and 13.49%were respectively. -For more data, please refer to the "Analysis Report of the Market Demand Prediction and Investment Strategic Planning of the Chinese Biopharmaceutical Industry in China Biopharmaceutical Industry"
Biopharmaceuticals are the method of using biological lives to produce drugs. Such as the use of genetically modified corn producing human antibodies, genetically modified cow -dairy glands A1 antibuttrase, etc. The biopharmaceutical industry has a broad prospect. Half of the medical products around the world have been biological synthesis. It will be widely used in treating cancer, AIDS, coronary heart disease, anemia, dysplasia, diabetes and other diseases. Most of the antibiotics that have been used in medicine come from microorganisms, such as erythromycin, schtitopycin, etc., and penicillin, rinsein, and galcinin used in injection The 1990s, my country's biopharmaceutical industry has achieved After sudden development, enterprises' investment in biopharmaceuticals increased at an average annual rate of 25%. In general, the development prospects of China's biomedical industry are promising. In the next 5-10 years, it will maintain a good development momentum of steady growth.
The development prospects of biopharmaceuticals are still very good. There are many types of biopharmaceuticals, which are targeted at animals, plants, people, biopharmaceuticals, including vaccines, drugs, health products, etc. The country attaches more attention. As long as there is a corresponding characteristic patent, the development prospects are still very high.
The development prospects of biopharmaceuticals are very good. The specific content is as follows: The major departments in the biopharmaceutical industry are committed to exploring the potential of biological organisms and substances in creating new drugs, vaccines and drug transportation systems. Professionals engaged in pharmaceutical and biotechnology work are engaged in intensive research and development to discover new information about genetic scholarship and apply cutting -edge technology to production. There are many different types of pharmaceutical and biotechnology work, including scientific researchers and engineers, clinic directors and technicians, technical writers and product sales representatives. Many pharmaceutical biotechnology work is trained by trained scientists and research assistants. The professional scientific journals read thousands of pages and attend regular meetings to understand the latest breakthroughs in genetic and pharmacology. They also proposed new assumptions and designed original research to understand how different types of drugs can effectively fight genetic diseases. For example, a scientist may want to create a drug that can correct a very special type of enzyme deficiency. He or she may try to create a synthetic enzyme or separate a biomass that can penetrate and repair damaged genes.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.